Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19890993 | 0.81 | MEN1 (0.50) | KMT2AMEN1MAPTHTTTSHR | |
| SCHEMBL19876831 | 0.79 | MAPT (0.52) | KMT2AMEN1MAPTHTTCA12 | |
| SCHEMBL22905163 | 0.77 | MEN1 (0.50) | KMT2AMEN1MAPTHTTGAA | |
| SCHEMBL18451634 | 0.72 | GAA (0.39) | KMT2AMEN1GAALMNASMN1; SMN2 | |
| SCHEMBL1871683 | 0.71 | GAA (0.59) | KMT2AMEN1HTTGAACA12 | |
| SCHEMBL9779930 | 0.70 | SMN1; SMN2 (0.50) | KMT2AMEN1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL6162575 | 0.67 | CXCR1 (0.40) | KMT2AMEN1MAPTHTTCA12 | |
| SCHEMBL23309599 | 0.66 | KDM4E (0.44) | KMT2AMEN1MAPTGAASMN1; SMN2 | |
| SCHEMBL31115168 | 0.66 | HTT (0.46) | KMT2AMEN1MAPTHTTTSHR | |
| SCHEMBL25585997 | 0.66 | KDM4E (0.40) | KMT2AMEN1MAPTGAACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247973-B2 | Antiviral benzodiazepine compounds | THE UNIVERSITY OF DURHAM (GB) | 2022-02-15 | — | — | US | disclosed |
| US-11247973-B2 | Antiviral benzodiazepine compounds | THE UNIVERSITY OF DURHAM (GB) | 2022-02-15 | — | — | US | disclosed |
| EP-3497096-B1 | AN ANTIMICROBIAL COMPOUND | THE UNIV OF DURHAM (GB) | 2021-11-10 | — | — | EP | disclosed |
| EP-3497096-B1 | AN ANTIMICROBIAL COMPOUND | THE UNIV OF DURHAM (GB) | 2021-11-10 | — | — | EP | disclosed |
| US-20210017138-A1 | An Antimicrobial Compound | THE UNIVERSITY OF DURHAM (GB) | 2021-01-21 | — | — | US | disclosed |
| US-20210017138-A1 | An Antimicrobial Compound | THE UNIVERSITY OF DURHAM (GB) | 2021-01-21 | — | — | US | disclosed |
| US-10406166-B2 | Antimicrobial compound | THE UNIVERSITY OF DURHAM (GB) | 2019-09-10 | — | — | US | disclosed |
| EP-3497096-A1 | AN ANTIMICROBIAL COMPOUND | The University of Durham (GB) | 2019-06-19 | — | — | EP | disclosed |
| WO-2018033714-A1 | AN ANTIMICROBIAL COMPOUND | THE UNIVERSITY OF DURHAM (GB) | 2018-02-22 | — | — | WO | disclosed |
| WO-2018033714-A1 | AN ANTIMICROBIAL COMPOUND | THE UNIVERSITY OF DURHAM (GB) | 2018-02-22 | — | — | WO | disclosed |
| EP-3283170-A1 | AN ANTIMICROBIAL COMPOUND | The University of Durham (GB) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016166546-A1 | AN ANTIMICROBIAL COMPOUND | THE UNIVERSITY OF DURHAM (GB) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10406166-B2 | Antimicrobial compound | FPR1, MPO, NISCH | KMT2A 4568/4885MEN1 1193/4885MAPT 3105/4885 |
| US-11247973-B2 | Antiviral benzodiazepine compounds | GABRA5, GABRA1, GABRA6 | KMT2A 1789/4885MEN1 2946/4885MAPT 1716/4885 |
| US-20210017138-A1 | An Antimicrobial Compound | FPR1, CFTR, FPR2 | KMT2A 4643/4885MEN1 1441/4885MAPT 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.